Tarceva is an oral, once-daily, reversible inhibitor of the EGFR signalling pathway. It is indicated as monotherapy for the treatment of patients with advanced non-small cell lung cancer whose tumours are driven by common EGFR gene-activating mutations. It is also indicated for patients with advanced pancreatic cancer in combination with chemotherapy.

Tarceva is available in the US, EU, Japan and more than 100 countries worldwide.